Litcius/Paper detail

Localized Surface Plasmon Resonance‐Enhanced Photocatalytic Antibacterial of In Situ Sprayed 0D/2D Heterojunction Composite Hydrogel for Treating Diabetic Wound

Zhengao Wang, Wei Li, Youzhun Fan, Cairong Xiao, Zhifeng Shi, Yunbing Chang, Guoyan Liang, Chengli Liu, Zurong Zhu, Peng Yu, Xuebin Yang, Zhiguo Song, Chengyun Ning

2024Advanced Healthcare Materials14 citationsDOIOpen Access PDF

Abstract

Chronic diabetic wounds pose significant challenges due to uncontrolled bacterial infections, prolonged inflammation, and impaired angiogenesis. The rapid advancement of photo-responsive antibacterial therapy shows promise in addressing these complex issues, particularly utilizing 2D heterojunction materials, which offer unique properties. Herein, an in situ sprayed Bi/BiOCl 0D/2D heterojunction composite fibrin gel with the characteristics of rapid formation and effective near-infrared activation is designed for the treatment of non-healing diabetes-infected wounds. The sprayed composite gel can provide protective shielding for skin tissues and promote endothelial cell proliferation, vascularization, and angiogenesis. The Bi/BiOCl 0D/2D heterojunction, with its localized surface plasmon resonance (LSPR), can overcome the wide bandgap limitation of BiOCl, enhancing the generation of local heat and reactive oxygen species under near-infrared irradiation. This facilitates bacterial elimination and reduced inflammation, supporting the accelerated healing of diabetes-infected wounds. This study underscores the potential of LSPR-enhanced heterojunctions as advanced wound therapies for chronic diabetic wounds.

Topics & Concepts

Materials scienceHeterojunctionSurface plasmon resonanceAngiogenesisInflammationComposite numberNanotechnologyPhotocatalysisWound healingChitosanOptoelectronicsMedicineBiomedical engineeringCancer researchNanoparticleImmunologyComposite materialChemical engineeringChemistryCatalysisEngineeringBiochemistryWound Healing and TreatmentsBurn Injury Management and OutcomesNanoplatforms for cancer theranostics